Is vaccination coverage a good indicator of age-appropriate vaccination? A prospective study from Uganda
Fadnes, Lars Thore; Nankabirwa, Victoria; Sommerfelt, Halvor; Tylleskär, Thorkild; Tumwine, James K.; Engebretsen, Ingunn Marie S.
Peer reviewed, Journal article
Published version
Date
2011-04-27Metadata
Show full item recordCollections
Original version
https://doi.org/10.1016/j.vaccine.2011.02.093Abstract
Background: Timely vaccination is important to protect children from common infectious diseases. We assessed vaccination timeliness and vaccination coverage as well as coverage of vitamin A supplementation in a Ugandan setting. Methods and findings: This study used vaccination information gathered during a cluster-randomized trial promoting exclusive breastfeeding in Eastern Uganda between 2006 and 2008 (ClinicalTrials.gov no. NCT00397150). Five visits were carried out from birth up to 2 years of age (median follow-up time 1.5 years), and 765 children were included in the analysis. We used Kaplan–Meier time-to-event analysis to describe vaccination coverage and timeliness. Vaccination coverage at the end of follow-up was above 90% for all vaccines assessed individually that were part of the Expanded Program on Immunization (EPI), except for the measles vaccine which had 80% coverage (95%CI 76–83). In total, 75% (95%CI 71–79) had received all the recommended vaccines at the end of follow-up. Timely vaccination according to the recommendations of the Ugandan EPI was less common, ranging from 56% for the measles vaccine (95%CI 54–57) to 89% for the Bacillus Calmette–Guérin (BCG) vaccine (95%CI 86–91). Only 18% of the children received all vaccines within the recommended time ranges (95%CI 15–22). The children of mothers with higher education had more timely vaccination. The coverage for vitamin A supplementation at end of follow-up was 84% (95%CI 81–87). Conclusions: Vaccination coverage was reasonably high, but often not timely. Many children were unprotected for several months despite being vaccinated at the end of follow-up. There is a need for continued efforts to optimise vaccination timeliness.
Publisher
ElsevierJournal
VaccineCopyright
Copyright 2011 Elsevier Ltd.
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs CC BY-NC-ND
Related items
Showing items related by title, author, creator and subject.
-
Making common sense of vaccines: an example of discussing the recombinant attenuated salmonella vaccine with the public
Dankel, Dorothy Jane; Roland, Kenneth L.; Fisher, Michael; Brenneman, Karen; Delgado Alemán, Ana; Santander, Javier; Baek, Chang-Ho; Clark-Curtiss, Josephine; Strand, Roger; Curtiss, Roy III (Journal article; Peer reviewed, 2014-07-10)Researchers have iterated that the future of synthetic biology and biotechnology lies in novel consumer applications of crossing biology with engineering. However, if the new biology’s future is to be sustainable, early ... -
Intramuscular vaccination of Atlantic lumpfish (Cyclopterus lumpus L.) induces inflammatory reactions and local immunoglobulin M production at the vaccine administration site
Erkinharju, Toni; Strandskog, Guro; Vågnes, Øyvind; Hordvik, Ivar; Dalmo, Roy Ambli; Seternes, Tore (Peer reviewed; Journal article, 2019)Atlantic lumpfish were vaccinated by intramuscular (im) or intraperitoneal (ip) injection with a multivalent oil‐based vaccine, while control fish were injected with phosphate‐buffered saline. Four lumpfish per group were ... -
Preparing for an influenza pandemic: Re-evaluating the use of the whole inactivated virus vaccine formulation. –A comparison of the immune responses after intramuscular or intranasal immunization with an influenza H5N1 whole inactivated virus vaccine in a murine model.
Trondsen, Monica (Master thesis, 2009-10-22)Influenza is a highly contagious respiratory disease which infects millions of people every year around the world. Influenza viruses undergo continuous antigen change and annual vaccination is an effective prophylactic ...